Endocrines (Jul 2022)

Molecular Basis for Hypochondroplasia in Japan

  • Tomohiro Ishii,
  • Masaki Takagi,
  • Keisuke Nagasaki,
  • Toshio Ohara,
  • Kentaro Miyai,
  • Tomoki Kosho,
  • Fumio Takada,
  • Gen Nishimura,
  • Tomonobu Hasegawa

DOI
https://doi.org/10.3390/endocrines3030034
Journal volume & issue
Vol. 3, no. 3
pp. 428 – 432

Abstract

Read online

Hypochondroplasia is an autosomal dominant genetic disorder due to a heterozygous pathogenic variant of the FGFR3 gene. The early diagnosis of hypochondroplasia is necessary, since growth hormone is effective for improving adult height. The genetic test for the FGFR3 gene could help the early diagnosis. The detailed characteristics of FGFR3 genotypes have not been widely investigated in Japan, except for a common pathogenic variant, p.Asn540Lys. This study retrospectively analyzed the FGFR3 genotypes of 35 patients from 30 families with hypochondroplasia (age, range 0–6 years, median 1 year) in Japan. The pathogenic variants of FGFR3 were identified in all the patients: p.Asn540Lys in 23 probands (76.7%), p.Lys650Gln in 2 (6.7%), p.Leu324His in 2 (6.7%), p.Leu324Val, p.Ser351Cys, and p.Lys650Thr in 1 each (3.2%). The median age at diagnosis, height SD score at diagnosis, or the severity of radiologic findings was not significantly different between probands with p.Asn540Lys and those with other variants. Intellectual disability or epilepsy was identified in seven patients with p.Asn540Lys, but none with other variants. The genetic test of FGFR3 can be useful for assessing the potential risk of neurological sequela in children with hypochondroplasia.

Keywords